Biocon Limited (BIOCON)

Name: Biocon Limited (BIOCON) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-09-20

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments.

Dati chiave

Capitalizzazione di mercato: ₹627 billion
Ricavi (esercizio chiuso a 2026-03-31): ₹167.8B
Utile netto: ₹3.9B
Margine lordo: 66.1%
Margine netto: 2.3%

Vedi grafici interattivi e bilanci completi →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Entrate totali	₹167.8B	₹150.5B	₹142.0B	₹109.3B
Utile lordo	₹110.9B	₹98.5B	₹92.9B	₹72.7B
Risultato Operativo (EBIT)	₹17.2B	₹16.3B	₹14.3B	₹16.3B
Reddito netto	₹3.9B	₹10.1B	₹10.2B	₹4.6B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di BIOCON. /companies/us/BIOCON

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.